German China
Search

UK: Microfluidics New Screening Company to Exploit Advances in Microfluidics and 3D Culture

| Editor: Alexander Stark

Screen In 3D is a new joint venture company set up by Amsbio and the University of Strathclyde tasked with the development of a novel microfluidic screening platform.

Related Company

Onco Screen service, the first application platform launched by Screen In 3D, is targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions using patient derived tissue.
Onco Screen service, the first application platform launched by Screen In 3D, is targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions using patient derived tissue.
(Source: Amsbio)

Glasgow/UK — The unique combination of microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids is designed to make drug discovery more closely relevant with what happens in the body. The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies do 100x more testing for the same costs as well as increasing productivity as it enables more experiments to be done on the same platform at the same time, thw company claims.

Onco Screen service — the first application platform launched by Screen In 3D is targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions using patient derived tissue.

Chosen by the Society for Laboration Automation & Screening (Slas Europe) as an innovation technology company (presented at Slas Europe 2018), the Oncoscreen service offers users the ability to reduce and replace animal models in cancer research. According to the suppler, the solution also provides a larger screening capability of patient derived tissue than existing services.

The Oncoscreen platform presents exciting possibilities for testing patient-derived multicellular tumor spheroids/organoids (comprising cancer cells, stromal cells, cancer stem cells and/or immune cells) for disease/biomarker-oriented drug activity and profiling using single- and pair-wise standard/targeted drug combinations. The JV is now actively seeking partners and investors to fast track development of further platforms. Additional R&D grants to enhance our immunotherapy and neuroscience programs are being applied for with collaborators.

(ID:45386977)